Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Diabetes Mellitus: Introduction

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Novocell, Inc.

Regenerative medicine·2007

Same author

Inflammation research Lifetime Achievement Award 2003, presented to Derek A. Willoughby.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2003

Same author

JNK: a new therapeutic target for diabetes.

Current opinion in pharmacology·2003

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Generating Human Pancreatic Tissue Slices to Study Endocrine and Exocrine Pancreas Physiology

Generating Human Pancreatic Tissue Slices to Study Endocrine and Exocrine Pancreas Physiology

Published on: March 15, 2024

Working for a cure for Type 1 diabetes. An interview.

Regenerative Medicine

|March 26, 2009

Summary

Dr. Alan J. Lewis, a leader in diabetes research, brings extensive experience from Novocell and Signal Pharmaceuticals to the Juvenile Diabetes Research Foundation (JDRF). His work focuses on advancing Type 1 diabetes research and therapies.

Area of Science:

Biomedical Research
Endocrinology
Regenerative Medicine

Background:

Dr. Alan J. Lewis has a distinguished career in biomedical research and leadership.
He has held significant roles at Novocell, Inc., focusing on stem cell therapies for diabetes.
His prior experience includes leadership at Signal Pharmaceuticals and Wyeth-Ayerst, with research in diabetes and other chronic diseases.

Discussion:

Dr. Lewis's leadership at the Juvenile Diabetes Research Foundation (JDRF) guides global Type 1 diabetes research.
His background in stem cell engineering and drug development informs JDRF's therapeutic strategies.
His extensive research experience spans multiple therapeutic areas, including diabetes, CNS, and inflammatory diseases.

Key Insights:

JDRF is a leading organization advocating for and funding Type 1 diabetes research.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Related Experiment Videos

Last Updated: Jun 24, 2026

Generating Human Pancreatic Tissue Slices to Study Endocrine and Exocrine Pancreas Physiology

Generating Human Pancreatic Tissue Slices to Study Endocrine and Exocrine Pancreas Physiology

Published on: March 15, 2024

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Dr. Lewis's expertise in stem cell technology and biopharmaceuticals is crucial for advancing diabetes treatments.

His career demonstrates a consistent focus on developing therapies for chronic diseases.

Outlook:

Continued advancement in Type 1 diabetes research and therapeutic development under Dr. Lewis's leadership.
Potential for novel cell and drug therapies emerging from JDRF-funded research.
Expansion of JDRF's influence in global diabetes research and advocacy.